Tuesday, 16 February 2016

Last week in Oxford, the Cystic Fibrosis Trust brought together gastrointestinal (GI) health experts from across Europe to look at the digestive complications that many people experience with cystic fibrosis. Along with the scientists and clinical staff, people with CF and their carers were represented. Below one of those parents, David Turner QC, gives us and insight on the research 'sandpit'.

Storm Imogen was doing its best to bend trees double as 35
scientists and clinicians gathered in Oxfordshire for a research “sandpit”
devoted to the problems which cystic fibrosis causes for the digestive tract.
An introduction from Dr Jon King (a Senior House Officer at St Mary’s,
Paddington, who also has cystic fibrosis) outlined just how debilitating – and
embarrassing – these complications can be. For many, digestive complications
are amongst the most significant effects of cystic fibrosis.

The sandpit was the brainchild of Dr Janet Allen, the Trust’s
Director of Strategic Innovation.

Remove collective ideas for research priorities and
season under the bright light of instant peer review.

The assembled company involved experts from all parts of the
UK, Germany, Belgium, the Netherlands and Spain. Discussions were free-rolling,
leaping between subjects such as gut microbiota, DIOS, the impact of
antibiotics, prebiotics and probiotics, gut acidity, gut motility, bicarbonate
channels, chloride channels and methane testing.

The discussion was superbly marshalled and directed by
facilitators from Know Innovation. By mid-morning of the second day the
attendees were working together in small multi-disciplinary teams to define a
novel research question and to justify the question’s relevance by explaining
how it would make a real difference to the lives of people with cystic
fibrosis. Proposals for further refinement and, potentially, applications for
future research funding, included improving gastrointestinal health by
manipulating microbiota, identifying biomarkers that could help develop
personalised dietary plans, and designing a new supplement to improve fat
absorption.

The aim of the sandpit was to stimulate discussion and to
provide the foundations for future, multi-disciplinary research collaborations
which might ultimately transform the lives of many. Not only was that aim
achieved, but a buzz was created which was palpable as everyone left to
confront the tail end of Imogen’s winds. All in all, this had been a
tremendously exciting and uplifting event!

Things
have come a long way since the 1960s when most children born with cystic
fibrosis failed to reach their fifth birthday – and there are now more adults
with cystic fibrosis in the UK than kids.

But
too many young people are dying early, too many families live with the grief
and the fear that cystic fibrosis brings, for us to let up until we have beaten
this cruel condition for good.

And
this goal is now more than a distant hope. It is one that we now genuinely
believe is within our grasp.

Yet
the nearer this comes, so it is more important than ever that we increase our
efforts to shorten the time it takes to get there, because every day, every
week, every year we spend means more lives lost and more suffering families.

The
development of a pipeline of new precision therapies that can extend life and
reduce the heavy treatment burden of cystic fibrosis is a major step forward,
and one that we want to see everyone benefit from as soon as possible.

But
it will not happen unless we make it so, and that’s the purpose of our ‘Stoppingthe Clock’ campaign. It will ensure the collective voice of the cystic fibrosis
community here in the UK is heard loud and clear by Vertex, the NHS,
politicians and others.

Access
to therapies that can make a difference to the lives of people with cystic
fibrosis is an essential part of our wider Fight for a Life Unlimited.

This
fight means we are investing where it matters to generate the best scientific
and clinical ideas and to accelerate the process to ensure these benefit people
with cystic fibrosis directly.

So,
as well as campaigning for vital therapies for today, we are investing in
world-class research centres tackling key issues like pseudomonas and NTM
infection to help generate the drugs of the future too.

And
we are developing plans to provide more capacity for vital clinical trials to
take place in the UK and helping to shape ideas to develop SmartCareCF to use
new technologies and data to empower people with cystic fibrosis and, where
possible, keep them out of hospital.

We
are developing new forms of information and support for people with cystic
fibrosis and their families – and shaping new programmes to promote activity
and empower and create new opportunities for young people living with the
condition.

And
we need the united voice of all those affected by cystic fibrosis, their
families, friends, clinical teams and others to help spread the word, amplify
our community’s voice and reach out to new supporters.

Together, we can and
will transform the lives of people with cystic fibrosis and achieve our goal of
a Life Unlimited. Please get on board and let’s make it happen!Want to help us do more transformational research and campaigning work? Donate now!

Friday, 29 January 2016

On 8–9
February, the Trust will be hosting a research ‘sandpit’ exploring issues
related to digestion in cystic fibrosis, a meeting bringing together experts
from within and beyond the world of cystic fibrosis. Here Dr Jon King shares his
experience of the often overlooked impact of cystic fibrosis on digestion.

A few months ago, the Cystic Fibrosis Trust
approached me to be a part of a research meeting (sandpit) to discuss possible
research avenues for gastrointestinal (GI) problems in cystic fibrosis (CF).

The Trust is exceptionally good at viewing CF
and its care holistically, and I realised what an immense impact GI problems
have on my daily life – dare I say it, rather more so than my lungs! During a
committee conference call, we joked that perhaps CF is actually a condition of
the GI tract with some lung involvement!

Of course when we think of CF, we think about
our lungs. When we fear the future, we worry about downward trends in
spirometry and worry about the need for transplants. We think about those times
when we have been caught out in public; short of breath, coughing and
spluttering, feeling quite awkwardly alien to everyone else around us. This is
CF… But is it?

Until 18 months ago, almost every morning for
over 10 years, I threw up acid and bile due to morning reflux. My face would
contort with the griping burning pain of my reflux between meals or whilst
eating certain foods. Triple therapy (pantoprazole, ranitidine and domperidone)
made no difference and when I had a pH manometry the surgeon did not believe
that I was complying with the drugs because the results were so extreme. I have
since had two operations on my stomach, the first failed, the second with the
addition of a metal mesh has worked well.

Reflux is annoying and can be really painful,
even leading to surgery; but to paraphrase Monty Python, apart from reflux,
what does the GI system do to us?

Well, what about Creon? Look at yourself. You’re
out with your friends, having a meal and you pull out a container and take more
tablets in one go than anyone round that table probably takes in a year. And
you have to do that almost every time you eat or drink. That is quite an impact
on our daily lives. Now that we are being deprived of 40,000s, I am on at least
70 25,000 capsules a day - it does allow me to perform my party trick of 24
tablets in one go though!

How about insulin? CF-related diabetes requires
careful blood-sugar monitoring and insulin regimes, and yet we rarely really
think about it; we deal with it as an adjunct to everything else, like taking a
vitamin tablet.

Which brings me conveniently on to the small
bowel GI effect of CF: fat-soluble vitamin malabsorption. What about the long-term
effect of the half a dozen or so more tablets (vitamins A+D, vitamin E and a
calcium tablet) for that? We have regular dexa scans to monitor bone density
because with the additive effect of regular steroid use, we have a high risk of
developing osteopaenia and eventually osteoporosis.

Alas, we are only at the upper GI system – we still
have the large bowel to tackle yet. Distal intestinal obstructive syndrome
(DIOS): excruciating pain requiring hospital admission for pain relief and
rehydration, sometimes an operation.

And what about steatorrhoea? I don’t know about
the readers but I spend an awful long part of my day in the toilet. How many
times have you been stood over a toilet wiping for three, four or five times
longer than you were ever sat on it?! And how many times have you had to flush
the loo so many times that someone has looked at you strangely as you return to
the living room? Do you even dare repeat this ritual in a public loo? I commend
you if you do – you are braver than me! I live in a small flat with my
girlfriend. I spent all my savings refurbishing but ran out of money before I
could afford the en suite door – to say that this can be a mood killer is an
understatement!

And our bowels can go completely the opposite
way with severe constipation, thanks to a perfect combination of sticky, fatty
steatorrhoeic stools and the thick mucus lining our guts. I once went 15 days
without going to the toilet at all. There can be advantages – I use all this
time on the toilet catching up with social media and replying to emails.

The constipation also affects our appetite intake,
which is essential for our calorie counts, and can even lead to regular
throwing up as the food has nowhere to go. Some readers may know that I cycled
to Barcelona last summer to raise money for the Cystic Fibrosis Trust. For five
days in a row I was so constipated that I was throwing up all my meals every
day - not a great way to tackle hundreds of kilometres of cycling.

So how do we deal with this severe constipation?
Yet more medication. Maybe four or more sachets of movicol a day and an equal
amount of NAC. Perhaps the occasional day on the toilet after a gatsrograffin
or picolax or Klean prep clear out. These are medications strong enough to
clear the bowel out for surgical or camera test procedures and yet we use them
merely to return to regular bowel movements!

But still, apart from painful reflux, stomach
operations, dozens of tablets a day, insulin regimes, malabsorption of vital
vitamins, high risk of osteoporosis, occasional DIOS, irregular bowel habits,
embarrassing steatorrhoea, sachets of laxatives a day and occasionally needing
to set a day or two aside for a full bowel clear out, what does the GI system
do to us?!

What oddities have you found with digestion and
cystic fibrosis? We can help those coming to the research sandpit really get to
grips with the subject –­ share your experiences with me, @JonKingBYD, on Twitter
with the hashtag #DigestCF.

Monday, 4 January 2016

The New Year is here! We're ready and raring to go in our fight for a life unlimited for everyone affected by cystic fibrosis!

Our Chief Executive, Ed Owen, lays out what will be an exciting year ahead and how you can resolve to help us throughout the year.

We are at a unique moment in the history of cystic fibrosis
– and 2016 must be a year of progress towards our ultimate goal.

New transformational therapies, exciting research programmes
and breakthroughs in genetic science are bringing closer the day when we will
beat this cruel condition for good.

And we, the Cystic Fibrosis Trust, will be unveiling new
ambitious plans to help ensure our united CF community seize the extraordinary
opportunities that exist to remove the limits CF imposes on all those whose
lives are affected.

But, as all of us touched by cystic fibrosis know, with hope
comes grief and pain.

Last year began for me with the funeral of Emily Thackeray,
a shining star who dedicated her life to campaign on issues like organ donation
– and ended with the dreadful news that 14-year-old Dylan Samuels had passed
away.

These, and all the other individual stories of those who
have lost their lives to cystic fibrosis, are the reasons we enter this year
with even more determination and focus to seize this special moment than ever
before.

2015 saw major steps forward.

The decision of the European Medicines Agency in November to
approve the use of Orkambi for those aged 12 and over with the most common CF
mutation in the UK (F508del) was very good news – as was its decision to extend
the use of Kalydeco to children under six and to adults with the R117H
mutation.

But this does not guarantee access, and this year our ‘Stopping
the Clock’ campaign will need to step up a gear to ensure both the NHS and
Vertex do the right thing so more people with CF are given access to these
gene-modifying therapies.

It is encouraging, too, to hear of the progress other
pharmaceutical companies are making to develop transformational drugs, as well
as further Vertex work to bring forward treatments affecting other mutations.

2015 also saw the long awaited results of the Phase 2b
clinical trial of a gene therapy developed by the Gene Therapy Consortium (GTC)
here in the UK. This study was only possible because of the extraordinary
support of the CF community over the last 15 years, and the results
demonstrated for the first time the potential for gene therapy as a potential
cystic fibrosis treatment.

We hope that a commercial partner can be found to take on
this work in 2016 and, as a result of the continued generosity of all our
supporters, the Trust is continuing to fund the GTC’s longer term ‘Wave 2’ work
to develop a potentially more impactful gene therapy product using a viral
agent to deliver the genetic material to the lungs of people with cystic
fibrosis.

2015 saw extraordinary developments in gene-editing
technology as a potential for treating, and perhaps curing, conditions like
cystic fibrosis.

The Trust is already investing in this field of research and
looking to build new collaborations to exploit the opportunities it presents. We
are also joining other groups to ensure we have the right regulations in place
to enable more vital research to take place to advance gene-editing work.

We continue to invest in research across a range of vital
areas – from transformational science to beat cystic fibrosis at source to work
confronting challenges like pseudomonas and NTM infections.

We will be expanding our research portfolio in 2016, and
looking to develop our commercial collaborations with industry to ensure good
ideas have every chance of progressing to real-life treatments for people with
cystic fibrosis.

And we are working well beyond research too.

We continue to work closely with clinicians and CF teams
across the UK to ensure all with cystic fibrosis have access to the best
possible care in the NHS.

To do so, we will continue to lobby to ensure proper NHS
funding is directed to support specialist CF centres – and we are soon to
announce new funding to support initiatives that promote innovation and
excellence in CF centres.

These will all be part of a range of new activities we will
be unveiling in the next few months as we seek to raise our game and our
ambitions to improve and transform the lives of those we are here for.

But we cannot do it alone. We need your support whether
through fundraising or donating, through campaigning or giving up your time to
volunteer.

2015 saw too many young people dying of cystic fibrosis. We
have no time to lose. The support of the CF community is extraordinary. But
there is much more to be done if we are to move closer to beating CF and ensure
a life unlimited.

As part of this challenge, we are asking you to make
resolutions for the New Year that can help make a difference. I, for one, will
make a clear commitment that the Trust will build on the improvements we have
been introducing to make 2016 an historic year in our work to create a
step-change in the impact we make.

I will also resolve to try and find the time to see more of
the greatest football team in the world. That’s Manchester City, just in case
you didn’t know!Find our more about how you can use your New Year's resolutions to join the fight for a life unlimited at www.cysticfibrosis.org.uk/resolutions

Sunday, 6 December 2015

The Cystic Fibrosis Trust has been working closely with the Outreach team in the UK Parliament to look at how we can continue to ensure cystic fibrosis and the issues of the CF community remain on the political agenda. As part of this, we're teaming up with Outreach team to host a 'digital discussion' with Ian Austin MP, ahead of a debate on access to precision medicines. Lucinda Blaser of the Outreach Team explains more.

Hi!
I’m Lucinda. I work in Outreach at the House of Commons.

I
work with communities in their digital spaces to share ways for them to get
involved in the work of Parliament and have their say on issues that are
important to them. We are trying to break down perceived barriers to engaging
with Parliament and one of the ways to do this is for us in Outreach to come to
you both in person or digitally!

One
of the ways the House of Commons is encouraging public participation with
debates that are happening is through a digital debate. Digital debates
are an outcome of the Speaker’s Commission on
Digital Democracy,
as part of their investigation into opportunities digital technology can bring
for parliamentary democracy. In their final report it was stated:

“We believe the public want the opportunity to have their say in
House of Commons debates; we also believe that this will provide a useful
resource for MPs and help to enhance those debates. We therefore recommend a
unique experiment: the use of regular digital public discussion forums to
inform debates held in Westminster Hall.”

Digital
discussions are a way for people to get involved in a debate and discuss their
thoughts and experiences with the MP who has proposed that debate. This is a
chance for the public to be heard by MPs taking part in the debate and to find
out more about the parliamentary process and what to do after this debate has
happened.

Digital
debates are opening up the process and helping the public to have their say
bringing together information from charities, organisations and the House of
Commons Library to one space for the public to discus.

On
Monday 8 December the cystic
fibrosis community will have the chance to come together for a digital
discussion, to share their stories about what it is like living with CF and
what access to drugs means for you. Ian Austin MP will be taking part in the
debate, and will use your stories to inform a special debate he is hosting in
Westminster a week later, which you will be able to stream online.

Please take part in the digital discussion
on Monday 7 December and make sure your voice is heard!

You can join in the digital discussion with Ian Austin MP over on Twitter from 5-6pm on Monday 7 December by using the hashtag #CFDebate

But what is 'precision medicine' and why does it matter? Dr Janet Allen, Director of Strategic Innovation, digs deeper.

On 20 January 2015, President Obama made this announcement
in his State of the Union address to the US nation:

“Tonight,
I’m launching a new Precision Medicine Initiative to bring us closer to curing
diseases like cancer and diabetes – and to give all of us access to the
personalised information we need to keep ourselves and our families healthier.”

This was an exciting, bold statement that frames the future
of treatments where individuals are treated as individuals. Recently Francis
Collins, Director of the USA National Institute of Health, gave his vision of
how this will be delivered, at the Faster Cures conference at the Milken
Institute (pictured). He described the programme as “big, hairy and audacious – and so it
should be.”

Dr Collins argued that the time is right to do this mainly
as a result of technologies coming together that will be able to inform
treatments; for example genomics, environmental effects, personal wearable
sensor technology. In the past, new treatments were approved based on the law
of averages. For instance, how does this treatment lower the average person’s
cholesterol compared to no treatment?

We
need to move away from this to a state where the right drug is given to the
right patient at the right time to achieve the right effect.

This is the aim of precision medicine; we need to convert
our thinking on how to keep people healthy and not see healthcare as only
having a role in treating ill-health. A key component in the development of
precision medicine is to engage with people as equal partners and not as
subjects for study. This thinking will transform the way we do scientific
research and is already creating the concept of ‘citizen scientists’. All of
this will not happen overnight but the very mention of precision medicine in
the State of the Union address creates momentum and it is clear that the
National Institutes of Health are up for the challenge and ready.

If you think that precision medicine is only for the ‘big’
conditions such as heart disease and cancer, see the extended quote from the
State of the Union address: “21st century businesses will rely on
American science, technology, research and development. I want the country that
eliminated polio and mapped the human genome to lead a new era of medicine –
one that delivers the right treatment at the right time. In some patients with
cystic fibrosis, this approach has reversed a disease once thought
unstoppable.”

These are truly interesting and exciting times and we need
to ensure that cystic fibrosis remains in the vanguard of developing precision
medicine to benefit each and every individual with the condition. This is
audacious but that shouldn’t stop us. As another speaker said:

Monday, 9 November 2015

Last
week gene editing hit the news with the story of young leukaemia patient Layla
and a pioneering treatment at Great Ormond Street. Here Dr Anoushka de Almeida,
Head of Research at the Cystic Fibrosis Trust, talks about the science behind
the story, and the ground-breaking work being funded by the Trust into using
genetic editing for treating cystic fibrosis.

We have recently heard on the media of clinicians
at Great Ormond Street Hospital using the revolutionary technique of gene
editing to treat a little girl, Layla, diagnosed with an aggressive cancer of
the bone marrow. All other conventional treatments failed and this was Layla
and her family’s last hope – and it seems to have worked.

So what did they do to produce such a
miracle? Layla’s doctors teamed up with researchers at UCL, led by Prof Waseem
Qasim, who has developed a novel approach to gene editing in immune cells (T-cells).
This approach involves taking donated T-cells from a healthy person, modifying
the genome using gene editing to enable them to attack cancer cells, and then
introducing them into the body. Previously, these cells had only been tested in
mice, so Layla was the first human to receive them. The gene editing technique they used involved
using a pair of 'molecular scissors’, a kind known as TALEN proteins, to
‘switch off’ certain receptors, making sure that the modified T-cells leave the
healthy cells alone and only attack leukaemia cells. Genes were also edited out
to make the new cells ‘invisible’, so that they wouldn't be destroyed by other
leukaemia drugs.

It is still early to say whether Layla has
been completely cured. The pharma company Cellectis, who collaborated with
Qasim, plans to start full clinical trials early in 2016, the results of which
will hopefully confirm that this isn’t just a one-off. If they are successful,
this is a huge step forward for treating leukaemia and other cancers, as well
as other conditions…

This leads me on to talking about the
research that’s currently underway using gene editing in cystic fibrosis…

As we know, cystic fibrosis is caused when there are mutations in both copies of the
CFTR gene. Recent studies have shown that the most common CF-causing mutation,
F508del, can be corrected using a gene editing technique called ‘CRISPR/Cas9’ (a
different method to what they used for Layla – but principally the same). The
first step in this technique is to cut out the dodgy bit of genome using the
‘molecular scissor’ complex, and the second step is to repair it by using a
donor DNA molecule containing the correct, non-faulty sequence. Now, this all
works well in isolated cells outside the body, but the efficiency of the repair
is very low. Also, difficulty arises when delivering both the molecular scissor
complex and the donor DNA into the
correct place in the body.

A different approach is being investigated by Dr Patrick Harrison and colleagues at
University College Cork. This work, which the Cystic Fibrosis Trust is
co-funding with the Cystic Fibrosis Foundation in the US, involves focusing on a small group of three rare CF-causing mutations.
(These mutations basically disrupt the processing of the messenger RNA molecule
which is normally needed to make the CFTR protein in cells). In all three
cases, there is an extra sequence in
the genome which interferes with the normal processing. Dr Harrison’s team is exploring
using the gene editing approach simply to cut out this extra piece in the
genome region that causes the problem. This CRISPR ‘knock-out’ strategy is more
efficient than repair, and only requires delivery of just the molecular scissor
complex; no donor DNA is required.

Dr Harrison’s
group has teamed up with groups in Europe and the US to take this work further
so that they can determine if all this hard work eventually leads to the normal
CFTR protein being produced, resulting in normal functioning of the particular lung
cells in cystic fibrosis.

So, off the back of the break-through in
little Layla, gene editing has re-entered the limelight. It can be safely said that it is not only a promising
prospect for cancer such as leukaemia, as her case unquestioningly
demonstrates, but also for genetic conditions like cystic fibrosis. The Cystic
Fibrosis Trust is fully supportive of this therapy and sees its exciting
potential, and we would be keen to engage in further cutting-edge research in
this area of genetic therapies.